查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004001

乳糜瀉治療市場：2026年至2032年全球市場預測（依治療方法、藥物類別、給藥途徑、通路、劑型、最終用戶、年齡層和適應症階段分類）

Celiac Disease Drugs Market by Therapy Type, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User, Age Group, Indication Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乳糜瀉治療市場價值將達到 17.3 億美元，到 2026 年將成長到 19 億美元，到 2032 年將達到 35.9 億美元，複合年成長率為 10.96%。

主要市場統計數據
基準年 2025 17.3億美元
預計年份：2026年 19億美元
預測年份 2032 35.9億美元
複合年成長率 (%) 10.96%

本書精彩地說明了不斷變化的治療和商業格局，以及這些格局如何影響乳糜瀉治療的發展。

乳糜瀉的治療模式已從主要依賴飲食管理轉變為以分子生物學、免疫學和藥學進步為驅動的蓬勃發展的治療領域。這種轉變提升了臨床目標，從透過避免麩質來控制症狀，轉向改善潛在的疾病機制、促進黏膜癒合和減少長期併發症。因此，包括製藥業、臨床醫生和保險公司在內的相關人員，如今正從兼顧臨床意義與實際應用和報銷情況的觀點來評估各種機會。

重塑乳糜瀉療法臨床開發、交付模式和商業化路徑的變革性變化策略概述

在治療領域，多種趨同的轉變正在發生，重塑研發人員和醫療保健系統的優先事項。首先，作用機制正加速多樣化。旨在分解攝取麩質的酶療法、旨在抑制抗原特異性免疫反應的靶向免疫調節劑以及靶向微生物組的益生菌，都基於不同的生物學原理。這種多方面的方法增加了差異化產品的可能性，但也使治療方法的比較評估變得更加複雜。

對 2025 年美國關稅政策變化對乳糜瀉治療藥物的研發、生產和供應鏈的累積影響進行定性分析。

近期關稅政策的變化進一步加劇了全球藥品供應鏈的複雜性，其影響波及乳糜瀉治療藥物研發、生產和分銷的各個環節。活性藥物成分和特殊輔料關稅的提高，推高了新型生技藥品和小分子製劑的上游工程投入成本。為此，相關企業正在重新評估其供應商組合，加快替代供應商的認證流程，並探索將生產環節轉移到近岸地區或重建關鍵生產流程，以降低貿易波動帶來的風險。

將治療方法、藥物分類、給藥途徑、分銷、劑型、最終用戶、年齡和適應症階段等因素轉化為策略重點的實用細分見解。

細分市場分析表明，不同類型的治療方法——酶療法、免疫調節療法和益生菌療法——之間存在差異，從而產生不同的臨床價值提案和操作要求。酵素療法優先考慮口服製劑的穩定性以及不受飲食環境影響的可預測活性。免疫調節劑需要複雜的安全性監測，在某些情況下還需要腸外給藥途徑。另一方面，益生菌則更注重菌株選擇、儲存管理和監管分類的細微差別。這些差異會影響研發進度、監管策略以及獲得支付方核准所需的證據材料。

重點區域見解，比較美洲、歐洲、中東和非洲以及亞太地區的促進因素、採用趨勢和政策環境。

在美洲，完善的診斷基礎設施、集中的胃腸病學專家以及充滿活力的風險投資和生物技術生態系統，正推動差異化治療方法的快速臨床開發和早期商業化。該地區的支付方框架通常強調療效比較和長期結果，傾向於選擇具有明確且可證實益處的治療方法。打入市場策略通常需要直接比較試驗和真實世界結果的數據，以證明其高價定價和納入處方藥目錄的合理性。

關注影響產品線優先排序、生產製造和市場進入決策的競爭與合作行為的企業級策略洞察。

乳糜瀉治療領域的主要企業正在推行差異化策略，將自主研發與策略合作結合。生物技術創新者通常專注於早期機制檢驗和市場定位，並利用目標臨床終點進行概念驗證（PoC）。同時，大型製藥企業通常憑藉先進的生產技術、監管專業知識和成熟的商業網路，實現規模經濟，在達成合作和許可協議後，加速後期研發並拓展市場。

為業界領導者提供切實可行的建議，以加速乳糜瀉治療藥物的研發，最佳化藥物取得途徑，並建立穩健的商業化模式。

首先，我們透過將關鍵終點納入試驗設計並儘早規劃真實世界數據（RWE）的收集，使臨床開發與支付者和患者的優先事項保持一致。這種方法縮小了監管核准與支付方接受度之間的差距，並強化了支持有利報銷的價值提案。其次，我們透過認證多家關鍵原料供應商、探索區域生產方案以及設計盡可能減少對低溫運輸依賴的劑型，實現供應鏈多元化並降低風險。這些措施降低了關稅和物流方面的風險，並提高了對需求波動的應對力。

對用於得出可靠且可操作的乳糜瀉治療見解的調查方法進行透明的概述。

本研究整合了第一手資料和第二手資料，全面概述了治療、商業和監管方面的趨勢。第一手資料包括與相關人員（包括臨床醫生、保險公司代表、供應鏈專家、業務拓展經理和患者權益組織）進行結構化訪談和討論，以收集關於未滿足需求、推廣障礙和證據要求的真實觀點。第二手資料則系統地回顧了同行評審文獻、臨床試驗註冊信息、監管指南和公開的企業資訊披露，以闡明發展趨勢和監管預期。

簡潔的結論整合了對希望了解和主導乳糜瀉治療發展趨勢的利害關係人的策略意義。

乳糜瀉的治療格局正日趨成熟，成為一個多方面的生態系統，其中基於機制的創新與複雜的商業性和營運現實相互交織。研發人員必須平衡科學抱負與實際考量，例如生產要求、給藥途徑的權衡、通路以及支付方驅動的證據要求，才能將臨床潛力轉化為患者可及性。供應鏈和政策的發展，包括關稅相關的變化，也為制定具韌性的研發和商業化策略帶來了更多挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的乳糜瀉治療市場

  • 酵素療法
  • 免疫調節療法
  • 益生菌療法

第9章 乳糜瀉治療市場：依藥物類別分類

  • 生物製藥
  • 低分子化合物

第10章：乳糜瀉治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第11章 乳糜瀉治療市場：依通路分類

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章：按劑型分類的乳糜瀉治療藥物市場

  • 注射藥物
  • 口服
    • 膠囊
    • 藥片

第13章 乳糜瀉治療市場：依最終使用者分類

  • 居家醫療環境
    • 由護理師管理
    • 自我管理
  • 醫院
  • 專科診所
    • 胃腸病診所
    • 一般診所

第14章 乳糜瀉治療市場：依年齡層別分類

  • 成人
  • 兒童

第15章：依適應症階段分類的乳糜瀉治療市場

  • 急性期管理
  • 維持治療

第16章 乳糜瀉治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 乳糜瀉治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 乳糜瀉治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國乳糜瀉治療市場

第20章：中國乳糜瀉治療市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptive Biotechnologies Corporation
  • Amyra Biotech AG
  • Anokion SA
  • Avaxia Biologics, Inc.
  • Calypso Biotech BV
  • Chugai Pharmaceutical Co., Ltd.
  • Entero Therapeutics, LLC
  • Equillium, Inc.
  • GlaxoSmithKline plc
  • ImmusanT, Inc.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Precigen, Inc.
  • Protagonist Therapeutics, Inc.
  • Provention Bio, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Topas Therapeutics GmbH
  • Zedira GmbH
Product Code: MRR-4659C87123C2

The Celiac Disease Drugs Market was valued at USD 1.73 billion in 2025 and is projected to grow to USD 1.90 billion in 2026, with a CAGR of 10.96%, reaching USD 3.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.73 billion
Estimated Year [2026] USD 1.90 billion
Forecast Year [2032] USD 3.59 billion
CAGR (%) 10.96%

Compelling contextual introduction to the evolving therapeutic and commercial environment shaping celiac disease drug development

Celiac disease has transitioned from a predominantly dietary management paradigm to a vibrant therapeutic landscape driven by advances in molecular biology, immunology, and formulation science. This shift has elevated the clinical ambition from symptom control through gluten avoidance to modifying underlying disease mechanisms, improving mucosal healing, and reducing long-term complications. As a result, stakeholders across industry, clinical practice, and payers now evaluate opportunities through a lens that balances clinical meaningfulness with practical delivery and reimbursement realities.

Concurrently, patient expectations are evolving. Increased awareness, improved diagnostic algorithms, and organized patient advocacy have amplified demand for therapies that reduce daily burden and provide measurable improvements in quality of life. Healthcare delivery is adapting to accommodate novel modalities and administration settings, while regulators and payers refine frameworks to assess comparative benefit and long-term value. Taken together, these factors create a complex, dynamic environment where therapeutic innovation must be clinically robust, commercially viable, and operationally executable to achieve adoption.

Strategic overview of the transformative shifts reordering clinical development, delivery models, and commercialization pathways in celiac disease therapeutics

The therapeutic landscape is experiencing multiple convergent shifts that are reshaping priorities for developers and healthcare systems. First, mechanistic diversification has accelerated: enzyme therapies aimed at degrading ingested gluten, targeted immunomodulators designed to blunt antigen-specific immune responses, and microbiome-directed probiotics each pursue distinct biological rationales. This pluralistic approach increases the probability of differentiated products while complicating comparative assessments across modalities.

Second, modality and molecule innovations have altered clinical trial design and regulatory engagement. Biologic agents and engineered small molecules require distinct manufacturing, stability, and delivery considerations, which affects timelines and capital intensity. Hybrid development strategies that pair oral formulations with targeted biologic adjuncts are emerging to reconcile efficacy with patient convenience. Third, distribution and care delivery models are evolving. Expansion of online prescription services and the maturation of homecare administration pathways are changing how therapies reach patients and how adherence is monitored, thereby influencing commercial models and payer interactions.

Finally, collaborative ecosystems are maturing; strategic partnerships between biotech innovators, contract development manufacturers, specialty pharmacies, and clinical networks are becoming essential. These alliances accelerate access to specialized capabilities, mitigate operational risk, and enable more flexible commercialization strategies that align with diverse routes of administration and end-user settings.

Qualitative analysis of the cumulative impacts of United States tariff policy shifts in 2025 on celiac disease drug development, manufacturing, and supply chains

Recent tariff policy changes have introduced added complexity to global pharmaceutical supply chains, with implications that ripple through development, manufacturing, and distribution of celiac disease therapies. Increased tariffs on active pharmaceutical ingredients and specialized excipients have raised upstream input costs for both novel biologics and small molecule formulations. In response, sponsors are reassessing supplier portfolios, accelerating qualification of alternative vendors, and evaluating nearshoring or repatriation of critical manufacturing steps to reduce exposure to trade-driven volatility.

These shifts also influence strategic decisions around clinical sourcing and manufacturing scale-up. Companies conducting multinational clinical trials face higher logistics costs for investigational product movement and sample transport, which can increase protocol complexity and necessitate greater contingency planning. Moreover, tariffs can affect choices of final dosage form and route of administration; therapies that rely on specialized injectable delivery systems or cold-chain dependent biologics may be disproportionately impacted compared with stable oral formulations.

Payers and procurement entities are also adjusting contracting expectations in light of cost pressures, prompting manufacturers to strengthen value propositions and explore risk-sharing arrangements. Overall, the tariff landscape encourages a multi-pronged response that includes supply chain diversification, strategic localization of critical processes, prioritization of cost-efficient dosage forms, and intensified negotiation with downstream distribution partners to preserve access and affordability.

Actionable segmentation insights that translate therapy, drug class, route, distribution, dosage form, end-user, age, and indication stage considerations into strategic priorities

Segmentation reveals that therapy type distinctions-enzyme therapy, immunomodulator therapy, and probiotic therapy-create discrete clinical value propositions and operational requirements. Enzyme therapies prioritize robust oral formulation stability and predictable activity across dietary contexts, immunomodulators demand sophisticated safety monitoring and potentially parenteral administration pathways, while probiotics emphasize strain selection, shelf-life management, and regulatory classification nuances. These differences influence development timelines, regulatory strategy, and the evidence package required for payer acceptance.

Drug class segmentation into biological and small molecule categories further determines manufacturing complexity and supply chain risk. Biologicals typically require specialized facilities, cold-chain logistics, and higher capital intensity, whereas small molecules offer more established manufacturing routes and potentially broader oral dosing flexibility. Route of administration segmentation between injectable and oral options affects patient adherence, site-of-care considerations, and reimbursement models; oral therapies favor self-administration and broader outpatient access, while injectables may necessitate clinic- or home-based nurse involvement.

Distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies highlights commercially relevant access routes. Hospital pharmacies, encompassing private and public hospitals, remain critical for acute and specialty clinic-dispensed biologics, while online pharmacies, including OTC and prescription services, enable broader geographic reach and convenience. Retail pharmacies, both chain and independent, support chronic maintenance therapies and front-line patient engagement. Dosage form segmentation-injectable formulation, oral capsules, oral tablets, and powder form-maps directly to stability, adherence, and manufacturing trade-offs that influence pricing and shelf-life strategies.

End-user segmentation into homecare settings, hospitals, and specialty clinics clarifies care pathways. Homecare, whether nurse assisted administration or self-administration, supports long-term maintenance therapies and reduces hospital burden, whereas hospital and specialty clinic settings remain central for acute management and complex immunomodulatory regimens. Age group segmentation, distinguishing adults and pediatrics, requires tailored safety, dosing, and formulation approaches, with pediatric development often demanding dedicated trials and formulations. Finally, indication stage segmentation between acute management and maintenance therapy shapes the evidence hierarchy needed for regulatory approval and payer reimbursement, with acute interventions often evaluated on rapid clinical endpoints and maintenance therapies judged on durability and long-term outcomes.

Key regional insights that compare drivers, adoption dynamics, and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

In the Americas, strong diagnostic infrastructure, concentrated centers of gastroenterology expertise, and an active venture and biotech ecosystem drive rapid clinical development and early commercialization of differentiated therapies. Payer frameworks in this region often emphasize comparative effectiveness and long-term outcomes, which favors therapies with clear demonstrable benefits. Market access strategies frequently require head-to-head evidence or real-world outcomes data to support premium pricing and formulary placement.

Europe, the Middle East & Africa presents a heterogeneous landscape where single-payer and multi-payer systems contrast with regions that have limited specialist access. Regulatory pathways in Europe value comprehensive safety data and often incorporate health technology assessment into reimbursement decisions. In several markets, centralized procurement and stringent price negotiation practices encourage manufacturers to develop strong health economic models and engage early with regional health authorities to align clinical development with reimbursement expectations.

Asia-Pacific exhibits rapid adoption potential driven by expanding diagnostics, growing specialty care capacity, and increasing public and private investment in biotechnology. However, regulatory environments vary widely, and manufacturers often need tailored development and commercialization roadmaps that account for local registration requirements, differential reimbursement mechanisms, and diverse distribution ecosystems. Across all regions, collaboration with local clinical networks, investment in real-world evidence generation, and adaptive pricing or access programs enhance the likelihood of successful adoption.

Strategic company-level insights highlighting the competitive and collaborative behaviors shaping pipeline prioritization, manufacturing, and market entry decisions

Leading organizations in the celiac disease therapeutic arena are pursuing differentiated strategies that combine internal development with strategic partnerships. Biotech innovators often concentrate on early-stage mechanistic validation and niche positioning, leveraging targeted clinical endpoints to demonstrate proof of concept. Larger pharmaceutical firms typically bring scale through advanced manufacturing, regulatory expertise, and established commercial networks, enabling accelerated late-stage development and broader market rollout when partnerships or licensing agreements align.

Across the sector, companies are investing in capabilities that de-risk production and improve time-to-market. This includes contract manufacturing relationships for biologics and small molecules, specialized formulation expertise for oral and powder forms, and digital health integrations for adherence and outcome tracking. Competitive dynamics are also driving consolidation of complementary assets, whether through asset acquisitions, co-development deals, or joint commercialization agreements. This collaborative approach helps distribute risk, pool resources for expensive late-stage trials, and harmonize clinical data packages for multinational submissions.

Finally, companies that succeed most consistently are those that integrate clinical differentiation with pragmatic commercialization planning-aligning evidence generation to payer expectations, building scalable manufacturing networks, and designing patient-centric delivery models that work across inpatient, specialty clinic, and homecare channels.

Actionable recommendations for industry leaders to accelerate development, optimize access, and build resilient commercialization models for celiac therapies

First, align clinical development with payer and patient priorities by embedding outcomes that matter into trial design and by planning real-world evidence generation early. This approach reduces the gap between regulatory approval and payer acceptance and enhances the value narrative that supports favorable reimbursement. Second, diversify and de-risk supply chains by qualifying multiple suppliers for critical inputs, exploring regional manufacturing options, and designing dosage forms that minimize cold-chain dependence when clinically feasible. These steps mitigate tariff and logistics vulnerabilities and improve responsiveness to demand shifts.

Third, pursue adaptive commercialization strategies that leverage online prescription services and retail networks for maintenance therapies while reserving hospital and specialty clinic pathways for complex immunomodulatory regimens. Coupling product launch plans with tailored patient support programs can enhance adherence and real-world outcomes. Fourth, prioritize strategic collaborations-partner with contract development organizations, specialty pharmacies, and clinical networks to access technical capabilities and accelerate market entry. Finally, invest in patient-centric formulation development and pediatric-friendly dosing options to broaden addressable populations and reduce barriers to adoption across care settings.

Transparent overview of the research methodology employed to generate robust, actionable insights into celiac disease therapeutics

This research synthesized primary and secondary inputs to develop a comprehensive understanding of therapeutic, commercial, and regulatory dynamics. Primary research consisted of structured interviews and discussions with stakeholders including clinicians, payer representatives, supply chain experts, business development leaders, and patient advocacy groups to capture real-world perspectives on unmet needs, adoption barriers, and evidence requirements. Secondary research included a systematic review of peer-reviewed literature, clinical trial registries, regulatory guidelines, and publicly available company disclosures to contextualize development trends and regulatory expectations.

Analytical methods integrated qualitative synthesis with cross-validation across data sources to ensure robustness. Segmentation frameworks were applied to interpret findings across therapy type, drug class, route of administration, distribution channel, dosage form, end-user, age group, and indication stage. Regional analyses considered regulatory, payer, and delivery system heterogeneity. The methodology emphasized triangulation of evidence, scenario-based assessment of policy impacts, and the translation of technical findings into actionable strategic recommendations for stakeholders.

Concise conclusion that synthesizes strategic implications for stakeholders seeking to navigate and lead in the evolving celiac disease therapeutic landscape

The celiac disease therapeutic landscape is maturing into a multifaceted ecosystem where mechanistic innovation intersects with complex commercial and operational realities. Developers must balance scientific ambition with pragmatic considerations-manufacturing requirements, route-of-administration trade-offs, distribution pathways, and payer evidence demands-to convert clinical promise into patient access. Supply chain and policy developments, including tariff-related shifts, add further imperatives to design resilient development and commercialization strategies.

Success will favor organizations that integrate rigorous clinical differentiation with flexible operational models, that engage early with payers and clinicians to align evidence generation with value expectations, and that build partnerships to complement internal capabilities. By pursuing patient-centric formulation strategies, diversifying supply chains, and tailoring commercialization to regional idiosyncrasies, stakeholders can improve the odds of achieving both clinical impact and sustainable access for new celiac disease therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Celiac Disease Drugs Market, by Therapy Type

  • 8.1. Enzyme Therapy
  • 8.2. Immunomodulator Therapy
  • 8.3. Probiotic Therapy

9. Celiac Disease Drugs Market, by Drug Class

  • 9.1. Biological
  • 9.2. Small Molecule

10. Celiac Disease Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral

11. Celiac Disease Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital
    • 11.1.2. Public Hospital
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Celiac Disease Drugs Market, by Dosage Form

  • 12.1. Injectable Formulation
  • 12.2. Oral
    • 12.2.1. Capsules
    • 12.2.2. Tablets

13. Celiac Disease Drugs Market, by End User

  • 13.1. Homecare Settings
    • 13.1.1. Nurse Assisted Administration
    • 13.1.2. Self Administration
  • 13.2. Hospitals
  • 13.3. Specialty Clinics
    • 13.3.1. Gastroenterology Clinics
    • 13.3.2. General Clinics

14. Celiac Disease Drugs Market, by Age Group

  • 14.1. Adults
  • 14.2. Pediatrics

15. Celiac Disease Drugs Market, by Indication Stage

  • 15.1. Acute Management
  • 15.2. Maintenance Therapy

16. Celiac Disease Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Celiac Disease Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Celiac Disease Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Celiac Disease Drugs Market

20. China Celiac Disease Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Adaptive Biotechnologies Corporation
  • 21.6. Amyra Biotech AG
  • 21.7. Anokion SA
  • 21.8. Avaxia Biologics, Inc.
  • 21.9. Calypso Biotech BV
  • 21.10. Chugai Pharmaceutical Co., Ltd.
  • 21.11. Entero Therapeutics, LLC
  • 21.12. Equillium, Inc.
  • 21.13. GlaxoSmithKline plc
  • 21.14. ImmusanT, Inc.
  • 21.15. Johnson & Johnson Services, Inc.
  • 21.16. Pfizer Inc.
  • 21.17. Precigen, Inc.
  • 21.18. Protagonist Therapeutics, Inc.
  • 21.19. Provention Bio, Inc.
  • 21.20. Sanofi S.A.
  • 21.21. Takeda Pharmaceutical Company Limited
  • 21.22. Topas Therapeutics GmbH
  • 21.23. Zedira GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)